Article
Cholinergic anti-inflammatory pathway and COVID-19
BioImpacts : BI
Document Type
Article
Publication Date
1-1-2022
Keywords
- Alpha 7 nicotinic acetylcholine receptor,
- COVID-19,
- Cholinergic anti-inflammatory pathway,
- Vagus nerve stimulation
Disciplines
Abstract
The cholinergic anti-inflammatory pathway (CAP) first described by Wang et al, 2003 has contemporary interest arising from the COVID-19 pandemic. While tobacco smoking has been considered an aggravating factor in the severity of COVID-19 infections, it has been suggested by some that the nicotine derived from tobacco could lessen the severity of COVID-19 infections. This spotlight briefly describes the CAP and its potential role as a therapeutic target for the treatment of COVID-19 infections using vagus nerve stimulation or selective alpha7 nicotinic acetylcholine receptor agonists.
Creative Commons License
Creative Commons Attribution-NonCommercial 4.0 International
ORCID ID
0000-0003-0867-2322; 0000-0002-6434-2136
DOI
10.34172/bi.2022.23980
Copyright
© 2022 The Author(s).
Citation Information
Danial Mehranfard and Robert C Speth. "Cholinergic anti-inflammatory pathway and COVID-19" BioImpacts : BI Vol. 12 Iss. 2 (2022) p. 171 - 174 ISSN: 2228-5652 Available at: http://works.bepress.com/robert-speth/94/